5 results about "Transmembrane glycoprotein" patented technology

A chimeric antigen receptor (CAR) comprises an extracellular antigen binding domain, wherein the extracellular antigen binding domain comprises a polypeptide that binds to an oncostatin-M receptor (OSMR), a leukemia inhibitory factor receptor (LIFR), a heterodimer of a transmembrane glycoprotein 130 (gp130) receptor and OSMR, and / or a heterodimer of a gp130 receptor and LIFR.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

A chimeric antigen receptor (CAR) comprises an extracellular antigen-binding domain, which comprises a polypeptide that binds to oncostatin M receptor (OSMR), leukemia inhibitory factor receptor (LIFR), a heterodimer between transmembrane glycoprotein 130 (gp130) receptor and OSMR, and / or a heterodimer between gp130 receptor and LIFR.

This invention discloses the application of the extracellular domain of the transmembrane glycoprotein NMB in the treatment and improvement of acute kidney injury, belonging to the field of medical technology, to study the therapeutic effect and mechanism of the extracellular domain of the transmembrane glycoprotein NMB on acute kidney injury. This invention utilizes the extracellular domain of the transmembrane glycoprotein NMB to treat a disease model of acute kidney injury, finding that the extracellular domain of the transmembrane glycoprotein NMB can effectively alleviate ischemia-reperfusion-induced acute kidney injury, promote kidney tissue repair, and inhibit the progression of acute kidney injury to chronic inflammation and fibrosis.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CD112, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.